Dr. Danielle Paglia

Danielle focuses her practice on patent prosecution and counseling in the pharmaceutical and biotech space – in particular, in the area of small molecule pharmaceuticals. Her experience includes preparation and prosecution of US and foreign patent applications for companies ranging from biotech startups to Big Pharma; strategic management of large, complex patent portfolios, including various aspects of life cycle management; freedom‑to‑operate and patentability analyses; intellectual property (IP) due diligence analyses in connection with in‑licensing and acquisition opportunities; and pre‑litigation analyses in anticipation of abbreviated new drug application (ANDA) litigation.

Danielle routinely advises clients on patent strategy across a range of chemical technologies, including novel and repurposed small molecules, heterobifunctional molecules, solid forms, such as polymorphs/salts/co-crystals, drug formulations, drug delivery systems, methods of treating disease, including clinical-stage patient population and dosing regimens, and methods of manufacturing, among others. She particularly enjoys advising new biotech startups to strategically grow, maintain and leverage their IP assets. 

Danielle obtained her PhD in organic chemistry from the University of California at Santa Barbara, where she worked on the synthesis of novel coenzyme Q10 analogs, prodrugs designed to cross the blood‑brain barrier, the development of microwave‑accelerated cross‑couplings using heterogeneous catalysis, and the design of a novel heterogeneous bimetallic catalyst for use in conventional and microwave‑accelerated cross‑coupling and tandem reactions. Before receiving her PhD, Danielle worked on the synthesis of water‑soluble ligand scaffolds at the College of the Holy Cross, where she completed her undergraduate degree in chemistry.

Danielle was recognized as “One to Watch” for Intellectual Property Law by The Best Lawyers in America in 2025 and 2026.